Skip to main content

Table 2 MIC profile of AMK and comparators for isolates of E. coli and K. pneumoniae

From: In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates

Isolates Antimicrobial agent Range Modal MIC50 MIC90 %S
All isolates AMK ≤0.5–>128 2 4 16 96
n = 1646 ATM ≤0.06–>64 0.06 0.125 32 85
  FEP ≤0.06–>64 0.06 0.06 32 87
  CAZ ≤0.06–>64 0.25 0.25 64 85
  C/T ≤0.06–>64 0.25 0.25 1 94
  CRO ≤0.06–>64 0.06 0.06 128 84
  CIP ≤0.015–>16 0.015 0.06 32 74
  IPM ≤0.06–>64 0.25 0.25 1 96
  MEM ≤0.06–>64 0.06 0.06 0.06 96
  TZP ≤0.25–>256 2 4 32 88
  TOB ≤0.06–>64 0.5 1 16 84
ESBL+isolates AMK 0.5–>128 16 8 32 87
n = 173 ATM ≤0.06–>64 64 64 128 9
  FEP ≤0.06–>64 128 128 128 16
  CAZ 0.125–>64 128 64 128 14
  C/T ≤0.06–>64 0.5 1 8 79
  CRO ≤0.06–>64 128 128 128 5
  CIP ≤0.015–>16 32 32 32 16
  IPM 0.125–>64 0.25 0.25 1 94
  MEM ≤0.06–>64 0.06 0.06 0.125 95
  TZP 0.25–>256 4 8 256 62
  TOB 0.25–>64 32 16 64 39
FEP-R isolates AMK 0.5–>64 8 8 64 79
n = 216 ATM 0.125–>64 128 64 128 6
  FEP 4–>64 128 128 128 0
  CAZ 0.5–>64 128 128 128 9
  C/T 0.125–>64 0.5 1 128 59
  CRO ≤0.06–>64 128 128 128 5
  CIP ≤0.015–>16 32 32 32 13
  IPM 0.06–>64 0.25 0.25 32 75
  MEM ≤0.06–>64 0.06 0.06 32 75
  TZP 0.25–>256 512 32 512 46
  TOB 0.25–>64 32 16 64 32
TZP-R isolates AMK 0.5–>64 16 8 64 78
n = 191 ATM ≤0.06–>64 128 32 128 36
  FEP ≤0.06–>64 128 16 128 39
  CAZ 0.25–>64 128 64 128 33
  C/T ≤0.06–>64 128 1 128 56
  CRO ≤0.06–>64 128 128 128 35
  CIP ≤0.015–>16 32 32 32 34
  IPM 0.125–>64 0.25 0.5 32 70
  MEM ≤0.06–>64 0.06 0.06 32 71
  TZP 32–>256 512 256 512 0
  TOB 0.025–>64 32 16 64 39
  1. AMK amikacin; ATM aztreonam; FEP cefepime; CAZ ceftazidime; C/T ceftolozane/tazobactam; CRO ceftriaxone, CIP ciprofloxacin; IPM imipenem; MEM meropenem; TZP piperacillin/tazobactam; TOB tobramycin